Synthetic and Natural Polymeric Drug Delivery Systems - A Comprehensive Overview of Polycaprolactone and Glucan Particles

Abstract:

The small size and large surface area of nano and microparticles are interesting properties for drug delivery, hypothetically capable of overcoming some limitations of conventional therapeutic medicine and diagnostic agents. Although their features are highly influenced by the polymer characteristics, these particles are known for encapsulating high amounts of drugs, improving their stability and bioavailability and enabling different administration routes. Among synthetic polymers, polycaprolactone (PCL) nanoparticles are widely studied in drug delivery due to the polymer excellent biocompatibility and degradability and for its ability to blend with other polymers. On its turn, among natural polymers, glucan has been emerging as a promising candidate for drug delivery particularly due to structure forming abilities and its immunomodulatory effects. Under the safe-by-design approach for the development of polymeric particles, this review encloses a comprehensive summary of production methods, physicochemical characteristics and immunotoxicity profiles of PCL and glucan particles developed for drug delivery.

• Periodical: Journal of Biomimetics, Biomaterials and Biomedical Engineering (Volume 59)
• Pages: 39-58
• DOI: https://doi.org/10.4028/p-ns8294
• Online since: February 2023
• Authors: Natalia Bernardi, Sandra Jesus*, Olga Borges
• Keywords: Drug Delivery, Glucan, Immunotoxicity, Microparticles, Nanoparticles, Polycaprolactone

References

[1] B.A. Omran, Chapter 1: Fundamentals of Nanotechnology and Nanobiotechnology, Nanobiotechnology: A Multidisciplinary Field of Science Springer Nature Switzerland AG, 2020. pp.1-36.

DOI: 10.1007/978-3-030-46071-6_1

[2] C.J. Cheng, G.T. Tietjen, J.K. Saucier-Sawyer, W.M. Saltzman, A holistic approach to targeting disease with polymeric nanoparticles, Nature Reviews Drug Discovery 14 (2015) 239-47.

DOI: 10.1038/nrd4503

[3] T. Pulingam, P. Foroozandeh, J.-A. Chuah, K. Sudesh, Exploring Various Techniques for the Chemical and Biological Synthesis of Polymeric Nanoparticles, Nanomaterials 12 (2022) 576.

DOI: 10.3390/nano12030576

[4] C.I.C. Crucho, M.T. Barros, Polymeric nanoparticles: A study on the preparation variables and characterization methods, Materials Science and Engineering: C 80 (2017) 771-84.

DOI: 10.1016/j.msec.2017.06.004

[5] A. Bhowmik, R. Khan, M.K. Ghosh, Blood Brain Barrier: A Challenge for Effectual Therapy of Brain Tumors, BioMed Research International 2015 (2015) 1-20.

DOI: 10.1155/2015/320941

[6] K. Park, A. Otte, F. Sharifi, J. Garner, S. Skidmore, H. Park, et al., Formulation composition, manufacturing process, and characterization of poly(lactide-co-glycolide) microparticles, Journal of Controlled Release 329 (2021) 1150-61.

DOI: 10.1016/j.jconrel.2020.10.044

[7] H. Pawar, S.R. Wankhade, D.K. Yadav, S. Suresh, Development and evaluation of co-formulated docetaxel and curcumin biodegradable nanoparticles for parenteral administration, Pharmaceutical Development and Technology 21 (2015) 725-36.

DOI: 10.3109/10837450.2015.1049706

[8] P. Ebrahimnejad, A. Sodagar Taleghani, K. Asare-Addo, A. Nokhodchi, An updated review of folate-functionalized nanocarriers: A promising ligand in cancer, Drug Discovery Today 27 (2022) 471-89.

DOI: 10.1016/j.drudis.2021.11.011

[9] W.H. De Jong, P.J. Borm, Drug delivery and nanoparticles:applications and hazards, Int J Nanomedicine 3 (2008) 133-49.

[10] N. Kamaly, B. Yameen, J. Wu, O.C. Farokhzad, Degradable Controlled-Release Polymers and Polymeric Nanoparticles: Mechanisms of Controlling Drug Release, Chemical Reviews 116 (2016) 2602-63.

DOI: 10.1021/acs.chemrev.5b00346

[11] D. Tuncel, H.V. Demir, Conjugated polymer nanoparticles, Nanoscale 2 (2010) 484.

[12] V.R. Sinha, K. Bansal, R. Kaushik, R. Kumria, A. Trehan, Poly-ϵ-caprolactone microspheres and nanospheres: an overview, International Journal of Pharmaceutics 278 (2004) 1-23.

DOI: 10.1016/j.ijpharm.2004.01.044

[13] A. Luciani, V. Coccoli, S. Orsi, L. Ambrosio, P.A. Netti, PCL microspheres based functional scaffolds by bottom-up approach with predefined microstructural properties and release profiles, Biomaterials 29 (2008) 4800-7.

DOI: 10.1016/j.biomaterials.2008.09.007

[14] P. L, Microcapsules PCL with Essential Oil Citronella, Advances in Tissue Engineering & Regenerative Medicine: Open Access 2 (2017).

DOI: 10.15406/atroa.2017.02.00024

[15] M.A. Woodruff, D.W. Hutmacher, The return of a forgotten polymer—Polycaprolactone in the 21st century, Progress in Polymer Science 35 (2010) 1217-56.

DOI: 10.1016/j.progpolymsci.2010.04.002

[16] C.-S. Wu, H.-T. Liao, Polycaprolactone-Based Green Renewable Ecocomposites Made from Rice Straw Fiber: Characterization and Assessment of Mechanical and Thermal Properties, Industrial & Engineering Chemistry Research 51 (2012) 3329-37.

DOI: 10.1021/ie202002p

[17] T.K. Dash, V.B. Konkimalla, Poly-є-caprolactone based formulations for drug delivery and tissue engineering: A review, Journal of Controlled Release 158 (2012) 15-33.

DOI: 10.1016/j.jconrel.2011.09.064

[18] K.W. Ng, H.N. Achuth, S. Moochhala, T.C. Lim, D.W. Hutmacher, In vivo evaluation of an ultra-thin polycaprolactone film as a wound dressing, Journal of Biomaterials Science, Polymer Edition 18 (2012) 925-38.

DOI: 10.1163/156856207781367693

[19] R.M. Mohamed, K. Yusoh, A Review on the Recent Research of Polycaprolactone (PCL), Advanced Materials Research 1134 (2015) 249-55.

DOI: 10.4028/www.scientific.net/amr.1134.249

[20] B. Azimi, P. Nourpanah, M. Rabiee, S. Arbab, Poly (∊-caprolactone) Fiber: An Overview, Journal of Engineered Fibers and Fabrics 9 (2014) 155892501400900.

DOI: 10.1177/155892501400900309

[21] D. Puppi, C. Mota, M. Gazzarri, D. Dinucci, A. Gloria, M. Myrzabekova, et al., Additive manufacturing of wet-spun polymeric scaffolds for bone tissue engineering, Biomedical Microdevices 14 (2012) 1115-27.

DOI: 10.1007/s10544-012-9677-0

[22] H. Fessi, F. Puisieux, J.P. Devissaguet, N. Ammoury, S. Benita, Nanocapsule formation by interfacial polymer deposition following solvent displacement, International Journal of Pharmaceutics 55 (1989) R1-R4.

DOI: 10.1016/0378-5173(89)90281-0

[23] C.E. Mora-Huertas, H. Fessi, A. Elaissari, Polymer-based nanocapsules for drug delivery, International Journal of Pharmaceutics 385 (2010) 113-42.

DOI: 10.1016/j.ijpharm.2009.10.018

[24] S.F. Chin, A. Azman, S.C. Pang, Size Controlled Synthesis of Starch Nanoparticles by a Microemulsion Method, Journal of Nanomaterials 2014 (2014) 1-7.

DOI: 10.1155/2014/763736

[25] G.J. Colmenares-Roldan, L.M. Agudelo-Gomez, R. Pinal, L.M. Hoyos Palacio, Production of bioabsorbible nanoparticles of polycaprolactone by using a tubular recirculating system, Dyna 85 (2018) 277-82.

DOI: 10.15446/dyna.v85n204.62292

[26] W. Badri, K. Miladi, Q.A. Nazari, H. Fessi, A. Elaissari, Effect of process and formulation parameters on polycaprolactone nanoparticles prepared by solvent displacement, Colloids and Surfaces A: Physicochemical and Engineering Aspects 516 (2017) 238-44.

DOI: 10.1016/j.colsurfa.2016.12.029

[27] S. Singh, A.N. Singh, A. Verma, V.K. Dubey, Biodegradable Polycaprolactone (PCL) Nanosphere Encapsulating Superoxide Dismutase and Catalase Enzymes, Applied Biochemistry and Biotechnology 171 (2013) 1545-58.

DOI: 10.1007/s12010-013-0427-4

[28] M. Dhanka, C. Shetty, R. Srivastava, Injectable methotrexate loaded polycaprolactone microspheres: Physicochemical characterization, biocompatibility, and hemocompatibility evaluation, Materials Science and Engineering: C 81 (2017) 542-50.

DOI: 10.1016/j.msec.2017.08.055

[29] J.B.E. Mendes, M.K. Riekes, V.M. de Oliveira, M.D. Michel, H.K. Stulzer, N.M. Khalil, et al., PHBV/PCL Microparticles for Controlled Release of Resveratrol: Physicochemical Characterization, Antioxidant Potential, and Effect on Hemolysis of Human Erythrocytes, The Scientific World Journal 2012 (2012) 1-13.

DOI: 10.1100/2012/542937

[30] Y. Wang, P. Li, Z. Peng, F.H. She, L.X. Kong, Microencapsulation of nanoparticles with enhanced drug loading for pH-sensitive oral drug delivery for the treatment of colon cancer, Journal of Applied Polymer Science 129 (2013) 714-20.

DOI: 10.1002/app.38582

[31] N. Sathyamoorthy, D. Magharla, P. Chintamaneni, S. Vankayalu, Optimization of paclitaxel loaded poly (ε-caprolactone) nanoparticles using Box Behnken design, Beni-Suef University Journal of Basic and Applied Sciences 6 (2017) 362-73.

DOI: 10.1016/j.bjbas.2017.06.002

[32] A.T. Alex, A. Joseph, G. Shavi, J.V. Rao, N. Udupa, Development and evaluation of carboplatin-loaded PCL nanoparticles for intranasal delivery, Drug Delivery 23 (2014) 2144-53.

DOI: 10.3109/10717544.2014.948643

[33] A. Maaz, W. Abdelwahed, I.A. Tekko, S. Trefi, Influence of nanoprecipitation method parameters on nanoparticles loaded with gatifloxacin for ocular drug delivery, International Journal of Academic Scientific Research 3 (2015) 01-12.

[34] F. Alexis, E. Pridgen, L.K. Molnar, O.C. Farokhzad, Factors Affecting the Clearance and Biodistribution of Polymeric Nanoparticles, Molecular Pharmaceutics 5 (2008) 505-15.

DOI: 10.1021/mp800051m

[35] R. Li, X. Li, L. Xie, D. Ding, Y. Hu, X. Qian, et al., Preparation and evaluation of PEG–PCL nanoparticles for local tetradrine delivery, International Journal of Pharmaceutics 379 (2009) 158-66.

DOI: 10.1016/j.ijpharm.2009.06.007

[36] S. Jesus, E.H. Fragal, A.F. Rubira, E.C. Muniz, A.J.M. Valente, O. Borges, The Inclusion of Chitosan in Poly-ε-caprolactone Nanoparticles: Impact on the Delivery System Characteristics and on the Adsorbed Ovalbumin Secondary Structure, AAPS PharmSciTech 19 (2017) 101-13.

DOI: 10.1208/s12249-017-0822-1

[37] M.R. Tavares, L.R.d. Menezes, J.C. Dutra Filho, L.M. Cabral, M.I.B. Tavares, Surface-coated polycaprolactone nanoparticles with pharmaceutical application: Structural and molecular mobility evaluation by TD-NMR, Polymer Testing 60 (2017) 39-48.

DOI: 10.1016/j.polymertesting.2017.01.032

[38] R.P. Singh, P. Ramarao, Accumulated Polymer Degradation Products as Effector Molecules in Cytotoxicity of Polymeric Nanoparticles, Toxicological Sciences 136 (2013) 131-43.

DOI: 10.1093/toxsci/kft179

[39] R.G.d.J. Vásquez Marcano, T.T. Tominaga, N.M. Khalil, L.S. Pedroso, R.M. Mainardes, Chitosan functionalized poly (ε-caprolactone) nanoparticles for amphotericin B delivery, Carbohydrate Polymers 202 (2018) 345-54.

DOI: 10.1016/j.carbpol.2018.08.142

[40] L.B. Prado, S.C. Huber, A. Barnabé, F.D.S. Bassora, D.S. Paixão, N. Duran, et al., Characterization of PCL and Chitosan Nanoparticles as Carriers of Enoxaparin and Its Antithrombotic Effect in Animal Models of Venous Thrombosis, Journal of Nanotechnology 2017 (2017) 1-7.

DOI: 10.1155/2017/4925495

[41] H. Danafar, U. Schumacher, MPEG–PCL copolymeric nanoparticles in drug delivery systems, Cogent Medicine 3 (2016) 1142411.

DOI: 10.1080/2331205x.2016.1142411

[42] B.C. Lehtovaara, M.S. Verma, F.X. Gu, Synthesis of curdlan-graft-poly(ethylene glycol) and formulation of doxorubicin-loaded core–shell nanoparticles, Journal of Bioactive and Compatible Polymers 27 (2012) 3-17.

DOI: 10.1177/0883911511432511

[43] M. Nasrollahzadeh, M. Sajjadi, Z. Nezafat, N. Shafiei, Polysaccharide biopolymer chemistry, (2021) 45-105.

DOI: 10.1016/b978-0-12-822108-2.00019-3

[44] Z. Cai, H. Zhang, Recent progress on curdlan provided by functionalization strategies, Food Hydrocolloids 68 (2017) 128-35.

DOI: 10.1016/j.foodhyd.2016.09.014

[45] J. Hwang, K. Lee, A.A. Gilad, J. Choi, Synthesis of Beta-glucan Nanoparticles for the Delivery of Single Strand DNA, Biotechnology and Bioprocess Engineering 23 (2018) 144-9.

DOI: 10.1007/s12257-018-0003-4

[46] National Center for Biotechnology Information.(2022). PubChem Compound Summary for CID 439262, beta-Glucan August 4, 2022: https://pubchem.ncbi.nlm.nih.gov/compound/beta-glucan.

[47] X.-B. Zhan, C.-C. Lin, H.-T. Zhang, Recent advances in curdlan biosynthesis, biotechnological production, and applications, Applied Microbiology and Biotechnology 93 (2011) 525-31.

DOI: 10.1007/s00253-011-3740-2

[48] M. Wang, C. Chen, G. Sun, W. Wang, H. Fang, Effects of curdlan on the color, syneresis, cooking qualities, and textural properties of potato starch noodles, Starch - Stärke 62 (2010) 429-34.

DOI: 10.1002/star.201000007

[49] J.-L. Zhou, F. Song, J.-F. Tian, W.-C. Nie, X.-L. Wang, Y.-Z. Wang, Electrostatic wrapping of doxorubicin with curdlan to construct an efficient pH-responsive drug delivery system, Nanotechnology 28 (2017) 295601.

DOI: 10.1088/1361-6528/aa75b5

[50] M.-Y. Kim, C.-M. Lee, J.-N. Kim, K.-O. Cho, K.-Y. Lee, Prevention of post-surgical peritoneal adhesion in rats using curdlan and gellan gum hydrogels, Macromolecular Research 20 (2013) 1289-93.

DOI: 10.1007/s13233-012-0184-1

[51] V. Vetvicka, L. Vannucci, P. Sima, β‐glucan as a new tool in vaccine development, Scandinavian Journal of Immunology 91 (2019).

DOI: 10.1111/sji.12833

[52] D. Akramienė, A. Kondrotas, J. Didžiapetrienė, E. Kėvelaitis, Effects of ß-glucans on the immune system, Medicina 43 (2007) 597.

DOI: 10.3390/medicina43080076

[53] W.-C. Song, Crosstalk between Complement and Toll-Like Receptors, Toxicologic Pathology 40 (2011) 174-82.

DOI: 10.1177/0192623311428478

[54] M. Zhang, J.A. Kim, A.Y.-C. Huang, Optimizing Tumor Microenvironment for Cancer Immunotherapy: β-Glucan-Based Nanoparticles, Frontiers in Immunology 9 (2018).

DOI: 10.3389/fimmu.2018.00341

[55] M. Novak, V. Vetvicka, β-Glucans, History, and the Present: Immunomodulatory Aspects and Mechanisms of Action, Journal of Immunotoxicology 5 (2008) 47-57.

DOI: 10.1080/15476910802019045

[56] L. Sun, Y. Zhao, The Biological Role of Dectin-1 in Immune Response, International Reviews of Immunology 26 (2009) 349-64.

[57] G.C.-F. Chan, W.K. Chan, D.M.-Y. Sze, The effects of β-glucan on human immune and cancer cells, Journal of Hematology & Oncology 2 (2009).

[58] B.-D. Kim, K. Na, H.-K. Choi, Preparation and characterization of solid lipid nanoparticles (SLN) made of cacao butter and curdlan, European Journal of Pharmaceutical Sciences 24 (2005) 199-205.

DOI: 10.1016/j.ejps.2004.10.008

[59] M. Colaço, A.P. Marques, S. Jesus, A. Duarte, O. Borges, Safe-by-Design of Glucan Nanoparticles: Size Matters When Assessing the Immunotoxicity, Chemical Research in Toxicology 33 (2020) 915-32.

DOI: 10.1021/acs.chemrestox.9b00467

[60] X. Jia, Q. Liu, S. Zou, X. Xu, L. Zhang, Construction of selenium nanoparticles/β-glucan composites for enhancement of the antitumor activity, Carbohydrate Polymers 117 (2015) 434-42.

DOI: 10.1016/j.carbpol.2014.09.088

[61] R.K. Subedi, K.W. Kang, H.-K. Choi, Preparation and characterization of solid lipid nanoparticles loaded with doxorubicin, European Journal of Pharmaceutical Sciences 37 (2009) 508-13.

DOI: 10.1016/j.ejps.2009.04.008

[62] Z. Nasrollahi, S.R. Mohammadi, E. Mollarazi, M.H. Yadegari, Z.M. Hassan, F. Talaei, et al., Functionalized nanoscale β-1,3-glucan to improve Her2+ breast cancer therapy: In vitro and in vivo study, Journal of Controlled Release 202 (2015) 49-56.

DOI: 10.1016/j.jconrel.2015.01.014

[63] T.K. Upadhyay, N. Fatima, D. Sharma, V. Saravanakumar, R. Sharma, Preparation and characterization of beta-glucan particles containing a payload of nanoembedded rifabutin for enhanced targeted delivery to macrophages, EXCLI J 16 (2017) 210-28.

[64] C. Wu, B. Chu, L. Kuang, B. Meng, X. Wang, S. Tang, Synthesis of β-1,3-glucan esters showing nanosphere formation, Carbohydrate Polymers 98 (2013) 807-12.

DOI: 10.1016/j.carbpol.2013.06.056

[65] S. Anusuya, M. Sathiyabama, Preparation of β-d-glucan nanoparticles and its antifungal activity, International Journal of Biological Macromolecules 70 (2014) 440-3.

DOI: 10.1016/j.ijbiomac.2014.07.011

[66] M. Tukulula, L. Gouveia, P. Paixao, R. Hayeshi, B. Naicker, A. Dube, Functionalization of PLGA Nanoparticles with 1,3-β-glucan Enhances the Intracellular Pharmacokinetics of Rifampicin in Macrophages, Pharmaceutical Research 35 (2018).

DOI: 10.1007/s11095-018-2391-8

[67] H. Vu-Quang, M. Muthiah, H.J. Lee, Y.-K. Kim, J.H. Rhee, J.-H. Lee, et al., Immune cell-specific delivery of beta-glucan-coated iron oxide nanoparticles for diagnosing liver metastasis by MR imaging, Carbohydrate Polymers 87 (2012) 1159-68.

DOI: 10.1016/j.carbpol.2011.08.091

[68] M. Agarwal, M.S. Murugan, A. Sharma, R. Rai, A. Kamboj, H. Sharma, et al., Nanoparticles and its Toxic Effects: A Review, International Journal of Current Microbiology and applied sciences 2 (2013) 76-82.

[69] A. Sukhanova, S. Bozrova, P. Sokolov, M. Berestovoy, A. Karaulov, I. Nabiev, Dependence of Nanoparticle Toxicity on Their Physical and Chemical Properties, Nanoscale Research Letters 13 (2018).

DOI: 10.1186/s11671-018-2457-x

[70] S. Jesus, M. Schmutz, C. Som, G. Borchard, P. Wick, O. Borges, Hazard Assessment of Polymeric Nanobiomaterials for Drug Delivery: What Can We Learn From Literature So Far, Frontiers in Bioengineering and Biotechnology 7 (2019).

DOI: 10.3389/fbioe.2019.00261

[71] L. Mazzarino, G. Loch-Neckel, L. dos Santos Bubniak, F. Ourique, I. Otsuka, S. Halila, et al., Nanoparticles Made From Xyloglucan-Block-Polycaprolactone Copolymers: Safety Assessment for Drug Delivery, Toxicological Sciences 147 (2015) 104-15.

DOI: 10.1093/toxsci/kfv114

[72] T. Sandle, 11 - Endotoxin and pyrogen testing, In: Sandle T, editor. Pharmaceutical Microbiology. Oxford, Woodhead Publishing, 2016. pp.131-45.

DOI: 10.1016/b978-0-08-100022-9.00011-6

[73] M.A. Dobrovolskaia, D.R. Germolec, J.L. Weaver, Evaluation of nanoparticle immunotoxicity, Nature Nanotechnology 4 (2009) 411-4.

DOI: 10.1038/nnano.2009.175

[74] D. Boraschi, P. Italiani, R. Palomba, P. Decuzzi, A. Duschl, B. Fadeel, et al., Nanoparticles and innate immunity: new perspectives on host defence, Seminars in Immunology 34 (2017) 33-51.

DOI: 10.1016/j.smim.2017.08.013

[75] T. Sandle, 12 - Sterilization and sterility assurance, In: Sandle T, editor. Pharmaceutical Microbiology. Oxford, Woodhead Publishing, 2016. pp.147-60.

DOI: 10.1016/b978-0-08-100022-9.00012-8

[76] Q. Jiao, L. Li, Q. Mu, Q. Zhang, Immunomodulation of Nanoparticles in Nanomedicine Applications, BioMed Research International 2014 (2014) 1-19.

DOI: 10.1155/2014/426028

[77] S. Hussain, J.A.J. Vanoirbeek, P.H.M. Hoet, Interactions of nanomaterials with the immune system, WIREs Nanomedicine and Nanobiotechnology 4 (2011) 169-83.

DOI: 10.1002/wnan.166

[78] S. Crotty, A brief history of T cell help to B cells, Nature Reviews Immunology 15 (2015) 185-9.

[79] C.A.J. Janeway, P. Travers, M. Walport, M.J. Shlomchik. Immunobiology: The Immune System in Health and Disease. New York: Garland Science; (2001).

[80] A.A. Shvedova, V.E. Kagan, B. Fadeel, Close Encounters of the Small Kind: Adverse Effects of Man-Made Materials Interfacing with the Nano-Cosmos of Biological Systems, Annual Review of Pharmacology and Toxicology 50 (2010) 63-88.

DOI: 10.1146/annurev.pharmtox.010909.105819

[81] M. Schmutz, O. Borges, S. Jesus, G. Borchard, G. Perale, M. Zinn, et al., A Methodological Safe-by-Design Approach for the Development of Nanomedicines, Frontiers in Bioengineering and Biotechnology 8 (2020).

DOI: 10.3389/fbioe.2020.00258

[82] S. Jesus, N. Bernardi, J. da Silva, M. Colaço, J.o. Panão Costa, P. Fonte, et al., Unravelling the Immunotoxicity of Polycaprolactone Nanoparticles—Effects of Polymer Molecular Weight, Hydrolysis, and Blends, Chemical Research in Toxicology 33 (2020) 2819-33.

DOI: 10.1021/acs.chemrestox.0c00208

[83] E.S. Abamor, O.A. Tosyali, M. Bagirova, A. Allahverdiyev, Nigella sativa oil entrapped polycaprolactone nanoparticles for leishmaniasis treatment, IET Nanobiotechnology 12 (2018) 1018-26.

DOI: 10.1049/iet-nbt.2018.5115

[84] J. S, Freeze Dried Chitosan/ Poly-ε-Caprolactone and Poly-ε-Caprolactone Nanoparticles: Evaluation of their Potential as DNA and Antigen Delivery Systems, Journal of Genetic Syndromes & Gene Therapy 4 (2013).

DOI: 10.4172/2157-7412.1000164

[85] Z. Hong, M. Yu, Z. Chen, W. Guo, J. Wang, Y. Feng, et al., Specifically targeted delivery of protein to phagocytic macrophages, International Journal of Nanomedicine (2015) 1743.

DOI: 10.2147/ijn.s75950

[86] M.H. Le, H.D. Do, H.H. Tran Thi, L.V. Dung, H.N. Nguyen, H.N. Tran Thi, et al., The dual effect of curcumin nanoparticles encapsulated by 1-3/1-6 β -glucan from medicinal mushrooms Hericium erinaceus and Ganoderma lucidum, Advances in Natural Sciences: Nanoscience and Nanotechnology 7 (2016) 045019.

DOI: 10.1088/2043-6262/7/4/045019

[87] H. Li, D. Liu, S. Li, C. Xue, Synthesis and cytotoxicity of selenium nanoparticles stabilized by α-D-glucan from Castanea mollissima Blume, International Journal of Biological Macromolecules 129 (2019) 818-26.

DOI: 10.1016/j.ijbiomac.2019.02.085

[88] J. Singh, S. Pandit, V.W. Bramwell, H.O. Alpar, Diphtheria toxoid loaded poly-(ε-caprolactone) nanoparticles as mucosal vaccine delivery systems, Methods 38 (2006) 96-105.

DOI: 10.1016/j.ymeth.2005.11.003

[89] V.G. Reshma, P.V. Mohanan, Assessment of Immunotoxicity and Oxidative Stress Induced by Zinc Selenium/Zinc Sulphide Quantum Dots, Frontiers in Nanotechnology 2 (2021).

DOI: 10.3389/fnano.2020.597382

[90] K. Baert, B. De Geest, H. De Greve, B. Devriendt, E. Cox, Duality of β-glucan microparticles: antigen carrier and immunostimulants, International Journal of Nanomedicine (2016) 2463.

DOI: 10.2147/ijn.s101881

[91] M.A. Dobrovolskaia, S.E. McNeil, Immunological properties of engineered nanomaterials, Nature Nanotechnology 2 (2007) 469-78.

DOI: 10.1038/nnano.2007.223

[92] M.A. Dobrovolskaia, Pre-clinical immunotoxicity studies of nanotechnology-formulated drugs: Challenges, considerations and strategy, Journal of Controlled Release 220 (2015) 571-83.

DOI: 10.1016/j.jconrel.2015.08.056

[93] S. Đorđević, M.M. Gonzalez, I. Conejos-Sánchez, B. Carreira, S. Pozzi, R.C. Acúrcio, et al., Current hurdles to the translation of nanomedicines from bench to the clinic, Drug Delivery and Translational Research 12 (2021) 500-25.

DOI: 10.1007/s13346-021-01024-2

[94] M. Schmutz, O. Borges, S. Jesus, G. Borchard, G. Perale, M. Zinn, et al., A methodological safe-by-design approach for the development of nanomedicines, Frontiers in Bioengineering and Biotechnology 8 (2020) 258.

DOI: 10.3389/fbioe.2020.00258

[95] S. Hua, M.B.C. de Matos, J.M. Metselaar, G. Storm, Current Trends and Challenges in the Clinical Translation of Nanoparticulate Nanomedicines: Pathways for Translational Development and Commercialization, Frontiers in Pharmacology 9 (2018).

DOI: 10.3389/fphar.2018.00790

[96] M.C. Operti, A. Bernhardt, S. Grimm, A. Engel, C.G. Figdor, O. Tagit, PLGA-based nanomedicines manufacturing: Technologies overview and challenges in industrial scale-up, International Journal of Pharmaceutics 605 (2021) 120807.

DOI: 10.1016/j.ijpharm.2021.120807